Get all your news in one place.
100’s of premium titles.
One app.
Start reading
Benzinga
Benzinga
Business
Vandana Singh

Why NeoGenomics Stock Is Plunging Today

  • NeoGenomics Inc's (NASDAQ:NEO) CEO Mark Mallon will step down as CEO and member of the Board, effective immediately
  • The Board has retained Russell Reynolds to search for the Company's next CEO
  • The Board has appointed current Chair Lynn Tetrault, Esq. as Executive Chair and established an Interim Office of the CEO. 
  • Read Next: Guardant Health Will Not Go With NeoGenomics Deal: Bloomberg.
  • The Company expects revenue for Q1 2022 to be below the low end of its prior guidance of $118 - $120 million, and EBITDA for Q1 2022 will be below the low end of its previous guidance of $(15) - $(12) million. 
  • The larger than anticipated EBITDA loss was primarily driven by higher than expected Clinical Services' cost of goods sold. 
  • NeoGenomics has withdrawn its 2022 annual financial guidance issued in February.
  • Price Action: NEO shares are 32.1% lower at $12.07 on the last check Tuesday.
Sign up to read this article
Read news from 100’s of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.